RIV is recommended for individuals aged 18 years and older. It is particularly advantageous for populations that are at higher risk of severe influenza complications, such as the elderly, healthcare workers, and individuals with chronic health conditions. Epidemiologists emphasize the importance of widespread vaccination to achieve herd immunity.
